cerapedics
-
Biologics
Cerapedics Announces Canadian Approval of its next-generation bone graft
Canada will be the first commercial market to launch i-FACTOR®+ Matrix WESTMINSTER, Colo., September 15, 2020 — Cerapedics, a private…
Read More » -
Biologics
Cerapedics Announces FDA approval of an IDE supplement
WESTMINSTER, Colo., July 22, 2020 — Cerapedics, a private ortho-biologics company, today announced the U.S. Food and Drug Administration (FDA)…
Read More » -
Biologics
Cerapedics Announces Results from Clinical Trial of i-FACTOR® Peptide Enhanced Bone Graft in Lumbar Fusion Surgery
WESTMINSTER, Colo., May 19, 2020 /PRNewswire/ — Cerapedics, a private ortho-biologics company, today announced that results from a clinical trial evaluating i-FACTOR Peptide…
Read More » -
Biologics
Cerapedics Announces FDA Approval of PMA Supplement Based on Two-Year Clinical Data
WESTMINSTER, Colo., Nov. 18, 2019 /PRNewswire/ — Cerapedics, a private ortho-biologics company, today announced the U.S. Food and Drug Administration (FDA) has…
Read More » -
Biologics
Cerapedics Announces Expansion of Colorado Headquarters
WESTMINSTER, Colo., July 8, 2019 /PRNewswire/ — Cerapedics, a private ortho-biologics company, today announced the expansion of the company’s headquarters located in the Denver metropolitan…
Read More » -
Biologics
Cerapedics Appoints Patrick O’Connor as Vice President of Clinical and Market Development
WESTMINSTER, Colo., June 24, 2019 /PRNewswire/ –Cerapedics, a privately-held orthobiologics company, today announced the appointment of Patrick O’Connor as Vice President of Clinical and…
Read More » -
Biologics
Cerapedics Announces ISASS Issued a new Bone Grafting Policy Statement that Features i-FACTOR™ Peptide Enhanced Bone Graft
WESTMINSTER, Colo., March 6, 2019 /PRNewswire/ –Cerapedics, a privately-held orthobiologics company, today announced that the International Society for the Advancement of Spine…
Read More » -
Biologics
Cerapedics Announces First Patients Enrolled in IDE Clinical Trial of P-15L Bone Graft for Transforaminal Lumbar Interbody Fusion Surgery
WESTMINSTER, Colo., July 30, 2018 /PRNewswire/ — Cerapedics, a privately-held orthobiologics company, today announced that the first patients have been enrolled in…
Read More » -
Financial
Cerapedics Announces Closing of $22 Million Financing
WESTMINSTER, Colo., July 13, 2018 /PRNewswire/ — Cerapedics, a privately-held orthobiologics company, today announced that the company completed a $22 million financing led by KCK…
Read More » -
Biologics
Cerapedics Receives 2018 MedTech Breakthrough Award for Best New Surgical Technology Solution
WESTMINSTER, Colo., June 13, 2018 /PRNewswire/ — Cerapedics, a privately-held orthobiologics company, today announced that it has been selected as a winner…
Read More » -
Biologics
Cerapedics Announces Presentation of Results from the IVANOS Study of i-FACTOR™ Peptide Enhanced Bone Graft in Uninstrumented Lumbar Posterolateral Spine Surgery
WESTMINSTER, Colo., May 21, 2018 /PRNewswire/ — Cerapedics, a privately-held orthobiologics company, today announced results from the IVANOS study evaluating i-FACTOR™ Peptide Enhanced…
Read More » -
Hospitals
Cerapedics Receives FDA IDE Approval to Initiate Study of P-15L Bone Graft for Transforaminal Lumbar Interbody Fusion Surgery
WESTMINSTER, Colo., March 14, 2018 /PRNewswire/ — Cerapedics, a privately-held orthobiologics company, today announced the company received approval from the U.S. Food…
Read More » -
Biologics
Cerapedics Announces i-FACTOR™ Peptide Enhanced Bone Graft Adopted by More than 150 Leading U.S. Hospitals
WESTMINSTER, Colo., Oct. 26, 2017 /PRNewswire/ — Cerapedics, a privately-held orthobiologics company, today announced that more than 150 leading U.S. hospitals have now…
Read More » -
Biologics
DSM Biomedical and Cerapedics partner for peptide enhanced bone graft
October 17, 2017 By Danielle Kirsh DSM Biomedical has partnered with Cerapedics to create and manufacture the next generation of peptide-enhanced bone graft. The partnerships…
Read More » -
Biologics
Cerapedics Announces Publication of Two-Year IDE Study Follow-Up Data on i-FACTOR™ Bone Graft in the Cervical Spine
WESTMINSTER, Colo., Sept. 12, 2017 /PRNewswire/ — Cerapedics, a privately-held orthobiologics company, today announced the publication of two-year follow-up data from an FDA…
Read More »